Goodwood Inc. Discloses 10.1% Stake in Cosciens Biopharma
Ticker: CSCIF · Form: SC 13D · Filed: Sep 6, 2024 · CIK: 1113423
Sentiment: neutral
Topics: 13D-filing, ownership-stake, pharmaceuticals
TL;DR
**Goodwood Inc. now owns 10.1% of Cosciens Biopharma. Big stake.**
AI Summary
On September 6, 2024, Goodwood Inc. filed an SC 13D, reporting beneficial ownership of 10.1% of Cosciens Biopharma Inc. common stock. This filing indicates a significant stake acquired by Goodwood Inc., which previously operated under the name Aeterna Laboratories Inc. and Aeterna Zentaris Inc.
Why It Matters
This filing signals a substantial investment by Goodwood Inc. in Cosciens Biopharma, potentially indicating a desire to influence the company's strategic direction or a belief in its future prospects.
Risk Assessment
Risk Level: medium — The filing indicates a significant ownership stake, which could lead to activist investor behavior or strategic shifts, but no specific immediate threats are detailed.
Key Numbers
- 10.1% — Ownership Stake (Percentage of Cosciens Biopharma Inc. common stock beneficially owned by Goodwood Inc.)
Key Players & Entities
- Goodwood Inc. (company) — Filing entity
- Cosciens Biopharma Inc. (company) — Subject company
- Peter Puccetti (person) — Group member of Goodwood Inc.
- Aeterna Zentaris Inc. (company) — Former name of subject company
- Aeterna Laboratories Inc. (company) — Former name of subject company
FAQ
What is the total number of shares of Cosciens Biopharma Inc. common stock outstanding?
The filing does not explicitly state the total number of outstanding shares, but it does indicate that Goodwood Inc. beneficially owns 10.1% of the common stock.
What is the CUSIP number for Cosciens Biopharma Inc. common stock?
The CUSIP number for Cosciens Biopharma Inc. common stock is 22112H101.
When was the name change from Aeterna Zentaris Inc. to Cosciens Biopharma Inc.?
The filing indicates a name change from Aeterna Zentaris Inc. on June 17, 2004.
What is the business address of Goodwood Inc.?
The business address of Goodwood Inc. is 212 King Street West, Suite 201, Toronto, A6, M5H1K5.
What is the primary SIC code for Cosciens Biopharma Inc.?
The primary SIC code for Cosciens Biopharma Inc. is 2834, Pharmaceutical Preparations.
Filing Stats: 2,414 words · 10 min read · ~8 pages · Grade level 9.6 · Accepted 2024-09-06 14:04:41
Key Financial Figures
- $1,505,500 — urchases. An aggregate of approximately $1,505,500, including brokerage commissions, was u
- $0.01 — ise of warrants at an exercise price of $0.01 per Share. The exercise of the warrants
Filing Documents
- formsc13d.htm (SC 13D) — 116KB
- ex99-1.htm (EX-99.1) — 12KB
- 0001493152-24-035256.txt ( ) — 129KB
From the Filing
SC 13D 1 formsc13d.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )* COSCIENS BIOPHARMA INC. (Name of Issuer) Common stock, no par value (Title of Class of Securities) 22112H101 (CUSIP Number) Peter Puccetti Goodwood Inc. 132 Trafalgar Road Oakville, Ontario L6J 3G5 (416) 203-2022 Alfred G. Smith, Esq. Shutts & Bowen LLP 200 S. Biscayne Blvd., Suite 4100 Miami, Florida 33131 (305) 358-6300 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) August 29, 2024 (Date of Event which Requires Filing of this Schedule) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 22112H101 Schedule 13D Page 2 of 9 1. Names of Reporting Persons. Goodwood Fund 2. Check the Appropriate Box if a Member of a Group (a) (b) 3. SEC Use Only 4. Source of Funds WC 5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Province of Ontario, Canada Number of Shares Beneficially Owned by Each Reporting Person With: 7. Sole Voting Power -0- 8. Shared Voting Power 221,570 9. Sole Dispositive Power -0- 10. Shared Dispositive Power 221,570 11. Aggregate Amount Beneficially Owned by Each Reporting Person 221,570 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares 13. Percent of Class Represented by Amount in Row (11) 7.2% 14. Type of Reporting Person CO CUSIP No. 22112H101 Schedule 13D Page 3 of 9 1. Names of Reporting Persons. Goodwood Inc. 2. Check the Appropriate Box if a Member of a Group (a) (b) 3. SEC Use Only 4. Source of Funds AF 5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Province of Ontario, Canada Number of Shares Beneficially Owned by Each Reporting Person with: 7. Sole Voting Power -0- 8. Shared Voting Power 221,570 9. Sole Dispositive Power -0- 10. Shared Dispositive Power 221,570 11. Aggregate Amount Beneficially Owned by Each Reporting Person 221,570 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares 13. Percent of Class Represented by Amount in Row (11) 7.2% 14. Type of Reporting Person OO CUSIP No. 22112H101 Schedule 13D Page 4 of 9 1. Names of Reporting Persons. Peter Puccetti 2. Check the Appropriate Box if a Member of a Group (a) (b) 3. SEC Use Only 4. Source of Funds AF 5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Canada Number of Shares Beneficially Owned by Each Reporting Person With: 7. Sole Voting Power -0- 8. Shared Voting Power 221,570 9. Sole Dispositive Power -0- 10. Shared Dispositive Power 221,570 11. Aggregate Amount Beneficially Owned by Each Reporting Person 221,570 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares 13. Percent of Class Represented by Amount in Row (11) 7.2% 14. Type of Reporting Person IN CUSIP No. 22112H101 Schedule 13D Page 5 of 9 The following constitutes the Schedule 13D filed by the undersigned (the “Schedule 13D”). Item 1. SECURITY AND ISSUER This under the laws of Canada (the “Issuer”). The address of the principal executive offices of the Issuer is c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7. Item 2. IDENTITY AND BACKGROUND. (a) This Schedule 13D is filed by following persons (the “Reporting Persons”): (i) Goodwood Fund, a mutual fund trust established under the laws of the Province of Ontario, with respect to the shares of the Common Stock (the “Shares”) directly owned by the Goodwood Fund; (ii) Goodwood Inc., an Ontario corporation, as the investment manager of Goodwood Fund, with r